Shares of Morepen Laboratories today surged 12 per cent after the company received approval from the US health regulator for two bulk drug facilities in Himachal Pradesh.
The stock soared 11.77 per cent to settle at Rs 35.60 on the BSE. During the day, it jumped 16.48 per cent to Rs 37.10.
On the NSE, shares of the company rose sharply by 11.93 per cent to end at Rs 35.65.
In terms of equity volume, 10.79 lakh shares of the company were traded on the BSE and over 65 lakh shares changed hands on the NSE during the day.
Morepen Laboratories today said it has received approval from the US health regulator for two bulk drug facilities in Himachal Pradesh manufacturing Atorvastatin Calcium and Montelukast Sodium, respectively.
While the Baddi facility has got US Food and Drug Administration (USFDA) nod to manufacture cholesterol reducing bulk drug Atorvastatin Calcium, the Masulkhana facility has received approval for manufacturing anti-asthma bulk drug Montelukast Sodium, the company said in a BSE filing.
Disclaimer: No Business Standard Journalist was involved in creation of this content
